Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease

Next Previous
Trial Profile

A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deupirfenidone (Primary)
  • Indications COVID-19 pneumonia; Post acute COVID 19 syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors PureTech Health

Most Recent Events

  • 12 Feb 2024 Status changed from completed to discontinued.
  • 24 May 2023 Primary endpoint (Change in distance walked on the six-minute walk test (6MWT)) has not been met, as per results presented at the 119th International Conference of the American Thoracic Society.
  • 24 May 2023 Results assessing the safety and efficacy of LYT-100 in presenting with respiratory complications patients with respiratory complications, presented at the 119th International Conference of the American Thoracic Society.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top